Followers | 249 |
Posts | 13692 |
Boards Moderated | 0 |
Alias Born | 05/19/2015 |
Thursday, October 06, 2022 4:02:24 PM
Dr. David KOO’s is a Business Leader!
KOO’s owns 38+% or 169+ million shares of RGBP preferred shares RGBPP!
https://www.marketscreener.com/business-leaders/David-Raymond-Koos-06H0YV-E/biography/
Many of us have made much bank trading RGBPP preferred shares as well as RGBP. Years ago Dr. KOO’s gave us free RGBPP preferred shares as a dividend. Maybe he will do the same again or with sybleu.
When stock is spun off and given to shareholders as a stock dividend the Nakedshorts will be responsible to deliver the dividends on there short shares. It’s a very good way to trap the shorts!
Latest RGBP developments
https://www.userwalls.news/n/regen-biopharma-begins-experiments-validating-proprietary-car-cell-therapy-3813657/
https://www.bloomberg.com/press-releases/2022-08-25/regen-biopharma-develops-novel-means-of-using-car-t-cell-immunotherapy-to-attack-solid-tumors
https://docoh.com/news/benzinga/28638284/regen-biopharma-develops?fromCompany=1589150
https://www.nasdaq.com/press-release/regen-biopharma-inc.-files-provisional-patent-application-on-second-generation
RGBP on the Fast Track!
Things looking up here:
San Diego, CA, March 30, 2022: Regen BioPharma, Inc. received communication from the U.S. Patent Office that certain claims in its application #15/820,324 entitled, “Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans” have been allowed. $RGBP $RGBPP 1:39 PM · Mar 30, 2022·[/b
]
San Diego, CA, March 30, 2022: Regen BioPharma, Inc. received communication from the U.S. Patent Office that certain claims in its application #15/820,324 entitled, “Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans” have been allowed.$RGBP $RGBPP
— Regen BioPharma Inc. (@TheRegenBio) March 30, 2022
On the next Big Fun RGBP Run with the right News, Deal, Partner or Buyout RGBP should get get the mother of all the RGBP Naked Short Squeezes IMO!
Now RGBP has much more going for us!
Regen BioPharma Inc's Company Profile
Business Description
Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.
Anyone can contact KOO’s but you have to leave a call back number that helps keep the Bull $hitters that don’t want to be identified from wasting his time!
Telephone: (619) 722-5505 ext: 800
Fax: (619) 330-2328
Email: david.koos@regenbiopharma.com
Maybacks Global Entertainment and ZEASN Technology Private Ltd. Sign Global Licensing Agreement • AHRO • Aug 8, 2024 7:00 AM
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • SNWV • Aug 8, 2024 6:59 AM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM
Btab Ecommerce Group, Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • BBTT • Aug 7, 2024 9:00 AM
Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update • HYDI • Aug 7, 2024 8:52 AM
North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • NBRI • Aug 5, 2024 9:00 AM